Detailed Information on Publication Record
2018
East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort
AKIYAMA, E., L.N.L. VAN AELST, M. ARRIGO, J. LASSUS, O. MIRO et. al.Basic information
Original name
East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort
Authors
AKIYAMA, E. (250 France), L.N.L. VAN AELST (250 France), M. ARRIGO (250 France), J. LASSUS (246 Finland), O. MIRO (724 Spain), J. CELUTKIENE (440 Lithuania), D.J. CHOI (410 Republic of Korea), A.. COHEN-SOLAL (250 France), S. ISHIHARA (250 France), K. KAJIMOTO (392 Japan), S. LARIBI (250 France), A.P. MAGGIONI (380 Italy), J. MOTIEJUNAITE (250 France), C. MUELLER (756 Switzerland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), J.J. PARK (410 Republic of Korea), N. SATO (392 Japan), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), J. ZHANG (156 China), Y.H. ZHANG (156 China), K. KIMURA (392 Japan), K. TAMURA (392 Japan), E. GAYAT (250 France) and A. MEBAZAA (250 France, guarantor)
Edition
European Journal of heart Failure, Hoboken, Wiley, 2018, 1388-9842
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 12.129
RIV identification code
RIV/00216224:14110/18:00103656
Organization unit
Faculty of Medicine
UT WoS
000434273000019
Keywords in English
acute heart failure
Tags
International impact, Reviewed
Změněno: 9/2/2019 22:23, Soňa Böhmová
Abstract
V originále
Acute heart failure (AHF) is a major health problem worldwide and trials to assess novel therapies are increasingly global, as a means to reduce costs, expedite timelines, provide broad applicability, and satisfy regulatory authorities.The significant geographic differences in patient characteristics, outcomes, and treatment effect may affect trial results and raise important questions about generalizability of the results to a broader population.